We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ACE Biosciences and Crucell Collaborate to Discover Antibody Therapies
News

ACE Biosciences and Crucell Collaborate to Discover Antibody Therapies

ACE Biosciences and Crucell Collaborate to Discover Antibody Therapies
News

ACE Biosciences and Crucell Collaborate to Discover Antibody Therapies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ACE Biosciences and Crucell Collaborate to Discover Antibody Therapies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ACE BioSciencesA/S and Crucell N.V. have entered a research and licensing agreement to discover antibody therapies to combat serious hospital-acquired infections, including those caused by antibiotic-resistant bacteria.
 
Under the terms of the agreement, Crucell gains exclusive rights to assay a number of proprietary protein targets that ACE BioSciences has isolated and extracted from the cell surface of relevant bacteria.

Crucell will develop antibodies opposite these targets and in-licence the most promising ones for use in its anti-infection product development programme.

ACE BioSciences will be eligible for royalty and milestone payments on any therapies derived from the collaboration. ACE BioSciences was advised by BioSciencemanagers Ltd.
 
Ms Ingelise Saunders, ACE BioSciences’ CEO commented, "We are delighted that a company of the stature and experience of Crucell should recognize the unique therapeutic potential of our protein targets in the fight against infection."

"This deal validates the quality of our proteomics expertise and underlines the potential of our work in this large and underserved therapeutic area. I am confident that this is the first of a number of deals which we will broker in the coming months."

Advertisement